8-K: Co-Diagnostics Faces Nasdaq Delisting Risk After Share Price Drops Below $1

Co-Diagnostics, Inc. (CODX) received a notice from Nasdaq on January 10, 2025, indicating that its common stock price has fallen below the minimum $1.00 per share required for continued listing.

Summary

• Co-Diagnostics, Inc. (CODX) received a notification from Nasdaq on January 10, 2025, stating that its common stock has traded below $1.00 for 30 consecutive business days, violating Nasdaq's Listing Rule 5550(a)(2).
• The company has until July 9, 2025, to regain compliance by maintaining a share price of $1.00 or higher for at least ten consecutive business days.
• CODX's stock will continue to trade on the Nasdaq Capital Market under the symbol CODX during this compliance period.
• If CODX fails to regain compliance by July 9, 2025, it may be eligible for an additional 180 days if it meets other listing requirements and intends to cure the deficiency, potentially through a reverse stock split.
• If the company does not meet these requirements, Nasdaq may proceed with delisting the company's securities.
• Co-Diagnostics intends to monitor its stock price and consider options to regain compliance with Nasdaq's listing requirements.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and the uncertainty surrounding the company's ability to regain compliance. While the company has time to address the issue, the situation presents a significant risk.

Positives

• The company has a grace period until July 9, 2025, to regain compliance.
• The stock will continue to trade on Nasdaq during the compliance period.
• The company may be eligible for an additional 180 days to regain compliance if certain conditions are met.
• Co-Diagnostics intends to actively monitor the situation and consider available options.

Negatives

• The company's stock price has fallen below the minimum required for continued listing on Nasdaq.
• Failure to regain compliance by July 9, 2025, could lead to delisting.
• The company faces uncertainty regarding its ability to meet Nasdaq's requirements.

Risks

• The primary risk is the potential delisting from the Nasdaq if the company cannot increase its stock price above $1.00 by the compliance date.
• Delisting could negatively impact investor confidence and the company's ability to raise capital.
• The company's market value of publicly held shares must meet continued listing requirements.
• There is a risk that the company will not be able to cure the deficiency or be eligible for an extension.

Future Outlook

Co-Diagnostics intends to actively monitor its stock price and consider available options to resolve the deficiency and regain compliance with Nasdaq Listing Rule 5550(a)(2).

Management Comments

• Brian Brown, Chief Financial Officer, signed the report on behalf of Co-Diagnostics, Inc.

Industry Context

Many small-cap companies face similar challenges in maintaining listing compliance, especially in volatile market conditions. The diagnostics industry is subject to regulatory and market fluctuations that can impact stock prices.

Comparison to Industry Standards

• Other companies in the diagnostics sector, such as QuidelOrtho and Bio-Rad Laboratories, generally maintain higher share prices due to stronger financial performance and market capitalization.
• Reverse stock splits are a common strategy employed by companies facing delisting to artificially increase their share price, but their long-term effectiveness varies.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment if the company is delisted.
• Employees may face uncertainty regarding the company's future.
• The company's ability to raise capital could be negatively impacted.

Next Steps

• Co-Diagnostics will actively monitor its stock price.
• The company will consider available options to resolve the deficiency.
• Co-Diagnostics will attempt to regain compliance with Nasdaq Listing Rule 5550(a)(2) by July 9, 2025.

Key Dates